Sign In
Buy PRENW
Prenetics Global Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.84 |
| EPS actual | -$1.14 |
| EPS Surprise | -35.93% |
| Revenue estimate | 36.85M |
| Revenue actual | 36M |
| Revenue Surprise | -2.31% |
| Release date | Feb 18, 2026 |
| EPS estimate | -$0.330 |
| EPS actual | -$1.77 |
| EPS Surprise | -436.36% |
| Revenue estimate | 33.434M |
| Revenue actual | 36.6M |
| Revenue Surprise | 9.47% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.533 |
| EPS Surprise | 3.07% |
| Revenue estimate | 26M |
| Revenue actual | 23.555M |
| Revenue Surprise | -9.40% |
| Release date | Sep 12, 2025 |
| EPS estimate | -$0.710 |
| EPS actual | -$0.94 |
| EPS Surprise | -31.94% |
| Revenue estimate | 21.7M |
| Revenue actual | 17.68M |
| Revenue Surprise | -18.53% |
Last 4 Quarters for Prenetics Global
Below you can see how PRENW performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 12, 2025 |
| Price on release | $0.0227 |
| EPS estimate | -$0.710 |
| EPS actual | -$0.94 |
| EPS surprise | -31.94% |
| Date | Price |
|---|---|
| Sep 08, 2025 | $0.0202 |
| Sep 09, 2025 | $0.0250 |
| Sep 10, 2025 | $0.0282 |
| Sep 11, 2025 | $0.0280 |
| Sep 12, 2025 | $0.0227 |
| Sep 15, 2025 | $0.0225 |
| Sep 16, 2025 | $0.0220 |
| Sep 17, 2025 | $0.0220 |
| Sep 18, 2025 | $0.0199 |
| 4 days before | 12.38% |
| 4 days after | -12.33% |
| On release day | -0.88% |
| Change in period | -1.49% |
| Release date | Nov 10, 2025 |
| Price on release | $0.0259 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.533 |
| EPS surprise | 3.07% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $0.0218 |
| Nov 05, 2025 | $0.0218 |
| Nov 06, 2025 | $0.0193 |
| Nov 07, 2025 | $0.0198 |
| Nov 10, 2025 | $0.0259 |
| Nov 11, 2025 | $0.0259 |
| Nov 12, 2025 | $0.0181 |
| Nov 13, 2025 | $0.0285 |
| Nov 14, 2025 | $0.0288 |
| 4 days before | 18.81% |
| 4 days after | 11.20% |
| On release day | 0% |
| Change in period | 32.11% |
| Release date | Feb 18, 2026 |
| Price on release | $0.0210 |
| EPS estimate | -$0.330 |
| EPS actual | -$1.77 |
| EPS surprise | -436.36% |
| Date | Price |
|---|---|
| Feb 11, 2026 | $0.0220 |
| Feb 12, 2026 | $0.0220 |
| Feb 13, 2026 | $0.0210 |
| Feb 17, 2026 | $0.0211 |
| Feb 18, 2026 | $0.0210 |
| Feb 19, 2026 | $0.0211 |
| Feb 20, 2026 | $0.0211 |
| Feb 23, 2026 | $0.0211 |
| Feb 24, 2026 | $0.0210 |
| 4 days before | -4.55% |
| 4 days after | 0% |
| On release day | 0.476% |
| Change in period | -4.55% |
| Release date | May 14, 2026 |
| Price on release | $0.0179 |
| EPS estimate | -$0.84 |
| EPS actual | -$1.14 |
| EPS surprise | -35.93% |
| Date | Price |
|---|---|
| May 08, 2026 | $0.0177 |
| May 11, 2026 | $0.0177 |
| May 12, 2026 | $0.0178 |
| May 13, 2026 | $0.0179 |
| May 14, 2026 | $0.0179 |
| May 15, 2026 | $0.0178 |
| May 18, 2026 | $0.0178 |
| May 19, 2026 | $0.0178 |
| May 20, 2026 | $0.0160 |
| 4 days before | 1.13% |
| 4 days after | -10.61% |
| On release day | -0.559% |
| Change in period | -9.60% |
Prenetics Global Earnings Call Transcript Summary of Q1 2026
Prenetics (IM8) repositioned itself from a diagnostics/lab business into a consumer health subscription play anchored by IM8. Q1 2026 continuing operations revenue was $36M (up ~333% Y/Y), with IM8 contributing $33.8M. Key operating metrics: 82k active subscribers, 8.8M servings in the quarter (servings up ~28% sequentially), IM8 gross margin ~64%, and 93% of IM8 revenue from subscriptions. Monthly IM8 revenue in May is tracking to ~$15.5M (implied ARR ~ $186M). Management completed a global rollout of quarterly subscriptions, which materially increased new customer AOV (to $240 in Q1 from $110 FY2025 baseline) and compressed payback; January 2026 cohort reached $587 cumulative revenue in 4 months and current cohorts are tracking to implied 12-month LTR of $900–$1,100 (versus $571 on mature cohorts). Guidance was raised: full-year 2026 IM8 revenue to $190M–$210M (from $180M–$200M); Q2 revenue expected $46M–$48M (IM8 $44M–$46M). Adjusted EBITDA guidance remains effectively unchanged; Q1 adjusted EBITDA loss was $5.6M. Cash and liquidity: pro forma financial resources ~ $147M after selling 510 BTC for $41.3M and holding cash/financial assets; no debt. Capital allocation priorities: share repurchase (program partially used, ~$19M deployed), accelerate DTC marketing where unit economics prove, product pipeline, international expansion. Product roadmap: three additional SKUs (hydration, creatine, kids gummies) launching Q4 2026 (not included in guidance) — management projects meaningful incremental LTV uplift from attach rates. Defensible moats cited: athlete equity-aligned partnerships (Beckham, Sabalenka, Giannis, Inter Miami), RCT-backed science (one completed RCT; two more underway), and an AI-driven creative/marketing engine (scale of ad testing across Meta and plans to diversify to TikTok/YouTube/AppLovin). Management emphasizes unit-economics discipline, continued margin improvements from scale, and significant upside from channel diversification and future geography/product expansion. Risks noted on the call: forward-looking guidance subject to the usual uncertainties, and some non-cash, non-operating items (loan liabilities and share consideration) remain being finalized in quarter close.
